China Sky One Medical, Inc.

SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Peng Lei, CEO of NeuroXess, a Sequoia firm, was invited to participate in Sequoia China's Sequoia Talk Series on "The Compound Interest of Innovation" at which he shared his knowledge of and experience with the latest technological innovations in the field of brain science. As the founder of a start-up firm, Peng noted that we are now in an era of technology-led entrepreneurship. Crossing the border from the internet to the realm of life sciences, he said that it behooves one and all to keep making future-oriented, innovative, ground-breaking discoveries and putting them into practice. Continue Reading NeuroXess Invited to Participate in Sequoia Talk about Breakthroughs in the Field of Life Sciences Rome was not built in a day. Influential innovations are the rewards for those who continuously invested in this sector. At the first Brain Sciences Theme Forum of 2022 World Artificial Intelligence Conference (WAIC) that just took place in September, NeuroXess launched its first integrated cranial parietal semi-implantable medical-grade brain-computer interface (BCI), a high-frequency EEG signal processor bundled together with a software and algorithm cloud platform. Peng said that the company has built up considerable expertise in related technologies and products. In his presentation on the company's core technology, he noted, "Our cortical electrodes and flexible deep electrodes featuring MEMS micro and nano technology are greatly superior to traditional medical devices both in terms of technical indicators and the size and flexibility of the electrode." In addition, NeuroXess is using silk protein as the wrapping material to assist the implantation of the electrodes. Peng said that this approach reduces the trauma and damage to the brain that can take place during the implantation process, while the material itself is more easily degradable and is a safer implantation aid. He continued, "At present, with our BCI devices, chips for signal collecting and processing are able to support channel addressing for a 16,000-channel chip and the simultaneous acquisition of 2000 channels. This is the feature that really sets our chips apart." Peng said that the company's newly-released algorithm cloud platform facilitates leveraging the capabilities of the Internet, AI, and cloud computing to analyze digital EEG signals, enabling the continuous overlay and sharing of algorithms and data on the cloud. He described it as similar to Tesla's self-driving function: the more cars there are on the road, the more accurate the L4 algorithm will be. Eventually, we will form a closed loop in the EEG algorithm, and the more people use it, the more accurate our final decoding algorithm will become. From September to December, 16 senior investors from Sequoia China and 40+ entrepreneurs from companies at the forefront of innovation will be invited to discuss the intersection of technology and healthcare, and discover and put into practice the breakthrough innovations that can guide our future by examining the best examples of existing achievements. SOURCE NeuroXess

SHANGHAI, Sept. 8, 2022 /PRNewswire/ -- The Brain Sciences Theme Forum of 2022 World Artificial Intelligence Conference (WAIC) was held at Shanghai World Exhibition and Convention Center on September 2. NeuroXess, a China-based high-tech life science company focusing on flexible electrode BCI (brain-computer interface) technologies, made its debut at the event with a new lineup of products, including NeuroInterface, the first integrated cranial parietal semi-implantable medical-grade BCI, CereCube, a high-frequency EEG signal processor, and MindExplorer, a software and algorithm cloud platform. Continue Reading NeuroXess founder and CEO Peng Lei said that the new offerings are, for the most part, targeted to two markets. For one, they will serve as a basic research tools platform for the scientific research market to support brain-related projects while, for the other, they can be used to advance clinical trials in stages while remaining in compliance with processes required with therapies for ALS, high paraplegia, blindness and other indications. The compact-sized NeuroInterface is an integrated cranial parietal semi-implantable BCI designed based on medical-grade implant standards. The BCI can support up to 256 channels, double that of similar applications which are limited to 128 channels. The 30KHz sampling rate can effectively acquire spike signals, while the 16-bit sampling ensures the quality of the EEG data, providing a high-quality data guarantee for the processing software. Moreover, the interface is compatible with various types of EEG signals sampled simultaneously, including spikes, LFP, and ECoG. The NeuroInterface offerings include three major flexible electrode BCIs that can meet different clinical needs when working with the cortex and the brain's deeper layers. They are Silktrode, a high throughput flexible deep electrode, Surftrode, a flexible cortical electrode, and Plextrode, a combined deep/cortical electrode. CereCube is NeuroXess' first high-frequency EEG signal processor. With a strong high-channel and high-frequency acquisition capability, the processor can support up to 2,048 channels, eight times that of traditional clinical products which are limited to 256 channels. Its medical-grade design provides an effective guarantee for the safety and effectiveness of use. Furthermore, to meet the design requirements for Class II medical devices (NMPA/FDA), the processor is compatible with the most common levels of electrical stimulation when applying SEEG and ECoG, as well as both analog and digital signals, and a variety of peripherals. MindExplorer is NeuroXess' software and algorithm cloud platform, which builds a digital brain bank through the information stored in the cloud to enable continuous product iteration. The massive digital brain bank can not only be used for analysis, but also deliver highly robust solutions that can help medical and scientific institutions meet the needs of different scenarios. Mr. Peng said that the company will extend the reach of its different scenario-based products by working on multiple scientific research lines, including implants, chips, electrodes, implant robots and algorithm databases, with the goal of delivering several new technological innovations every year. SOURCE NeuroXess

HARBIN, China, Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today provided an update on its business. "Despite the global economic recession, we continue to experience strong demand for our products in China since they address common everyday ailments and are reasonably priced, with consumers only paying a small portion of the cost while the remainder is covered by healthcare insurance," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Best-selling products such as our Slim Patch continue to do well since consumers are more likely to spend on weight loss products at the expense of other discretionary items. In addition, we have a high degree of customer loyalty, especially with our weight loss products, due to our successful advertising campaign in 2008." "Our pipeline of new drugs is robust and we continue to add new sales agents to keep up with the rapid development of the Chinese pharmaceutical market," said Mr. Yan-Qing Liu. "We are currently looking at even more creative promotional and marketing strategies as we continue to launch a host of new and exciting products in 2009. Overall, we believe that we are well positioned to execute on our growth strategy and look forward to continued strong financial performance." About China Sky One Medical, Inc. China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit . Safe Harbor Statement Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. CONTACT: Mr. Yu-Bo Hao, CFO of China Sky One Medical, Inc., +86-0451-53994069, china_sky_one@yahoo.cn; or Investor Relations, Mr. Crocker Coulson, President of CCG Investor Relations, +1-646-213-1915, crocker.coulson@ccgir.com Web site: